Unique Immunotherapy Combos Evaluated in Advanced Melanoma

Source: Targeted Oncology, July 2021

Immune-checkpoint inhibitor (ICI) therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.1,2 In patients with advanced, ICI-refractory melanoma (either primary or acquired resistance), the rate of response to retreatment with ICIs or chemotherapy is poor.

READ THE ORIGINAL FULL ARTICLE